Zoetis Inc. (ZTS) stock
Close on Nov 12, 2026Market cap $34.28BP/E 14.0Yield 2.45%
Zoetis Inc. grew revenue 0.9% to $9.49B over the twelve months to Sep 30, 2026. Free cash flow was $2.24B, down 2.1% from a year earlier. At the latest close the market valued the company at $34.28B, 14.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $34.28B
- P/E ratio
- 14.0
- Price to sales
- 3.61
- Price to book
- 10.38
- Dividend yield
- 2.45%
- Free cash flow yield
- 6.52%
Fundamentals
- Revenue
- $9.49B
- Net income
- $2.51B
- EPS, diluted
- $5.93
- Free cash flow
- $2.24B
- Book value per share
- $8.02
- Diluted shares
- 412M
Trading
- Next earnings
- Feb 11, 2027 (estimated, before the open)
- Previous close
- $82.57
- Open
- $82.69
- Day's range
- $82.48 – $83.84
- Volume
- 4,389,343
- Average volume (20 days)
- 4,644,445
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.78
- 52-week range
- $68.77 – $132.49
- RSI (14 days)
- 57.3
- Volatility (1 year)
- 38.1%
- Relative volume
- 0.84×
- WACC
- 7.8%
On 3 of our idea lists: Buyback cannibals, Shareholder yield, Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZTS | S&P 500 | Difference | ZTS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.7% | -2.7% | +12.4 pts | ||
| 3 months | +12.8% | -1.7% | +14.6 pts | ||
| Year to date | -33.0% | +11.9% | −44.9 pts | ||
| 1 year | -30.5% | +12.0% | −42.5 pts | ||
| 3 years | -49.1% | +78.2% | −127.3 pts | -20.1% | +21.2% |
| 5 years | -59.6% | +73.2% | −132.8 pts | -16.6% | +11.6% |
| 10 years | +78.6% | +309.6% | −231.1 pts | +6.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zoetis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Zoetis
Pharmaceutical Preparations
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products, and precision animal health solutions. The enterprise organizes operations into United States and International segments, offering therapies across companion animals and livestock. Core categories include parasiticides, dermatology, vaccines, anti-infectives, and pain management products, alongside diagnostics and genetic tests. The company serves veterinarians, livestock producers, and pet owners through direct sales, veterinary distributors, retail pharmacies, and e-commerce channels.
Company profile, executives and historyZoetis stock: common questions
What is Zoetis's stock price?
ZTS closed at $82.96 on Nov 12, 2026, up 0.47% on the day. Over the past 52 weeks it traded between $68.77 and $132.49.
What is Zoetis's market cap?
Zoetis was worth $34.28B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ZTS's P/E ratio?
ZTS trades at 14.0 times earnings, based on diluted earnings per share of $5.93 over the twelve months to Sep 30, 2026.
How much revenue does Zoetis make?
Zoetis reported revenue of $9.49B for the twelve months to Sep 30, 2026, up 0.9% from a year earlier.
Does Zoetis pay a dividend?
Yes. Zoetis paid $2.03 per share over the last twelve months, a yield of 2.45% at the latest price, and has raised its annual dividend 13 years in a row.
When does Zoetis report earnings next?
Zoetis is expected to report Q4 FY2026 results on Feb 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ZTS stock performed over the past year?
Including dividends, ZTS returned -30.5% over the past year, against +12.0% for the S&P 500.
How many ZTS shares are sold short?
17M shares were sold short at the latest FINRA report, 4.05% of the float, or 4.8 days of average trading volume.
Who are Zoetis's competitors?
Companies most similar to Zoetis by business, industry and size include ELAN, VTRS, PAHC, GRFS, TEVA.
See a number that looks wrong?